Journal of veterinary internal medicine · 2009
Serum cardiac troponin I concentration in retired racing greyhounds.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
LaVecchio D, Marin L M, Baumwart R, Iazbik M C, Westendorf N, Couto C G
Аннотация
BACKGROUND: Cardiac troponin I (cTnI) is a polypeptide found specifically in cardiac muscle tissue that has been used as a diagnostic and prognostic indicator of cardiomyopathy. Increases in cTnI are associated with myocardial pathologic processes. However, high serum cTnI concentrations have been observed in normal Greyhounds.
HYPOTHESIS: We hypothesized that Greyhounds have cTnI concentrations higher than non-Greyhound dogs, and that a separate reference range should be established for Greyhounds.
ANIMALS: Blood samples were collected from the jugular vein from a group of 20 healthy Greyhound blood donors.
METHODS: Analysis of serum cTnI was performed with an immunoassay system with a detection level of 0.01 ng/mL, as described previously. The Greyhound values were compared with 2 groups of Boxers with and without arrhythmogenic right ventricular cardiomyopathy (ARVC), and to a group of non-Boxer control dogs from a previous study.
RESULTS: The mean cTnI concentration in Greyhounds was significantly higher (P < .0001) than that in non-Greyhound control dogs, although not significantly different from normal Boxers (P= .50), or Boxers with ARVC (P= .58). Greyhound serum cTnI concentrations were in the range found in Boxers with ARVC. The proposed reference range for cTnI in Greyhounds is 0.05-0.16 ng/mL.
CONCLUSIONS AND CLINICAL IMPORTANCE: Greyhounds have a reference range for serum cTnI concentrations that differs from that of other previously published reference ranges for dogs of other breeds. Until a broader database and more precise reference range can be established, caution should be exercised in interpreting serum cTnI concentrations in Greyhounds with suspected cardiac disease.
HYPOTHESIS: We hypothesized that Greyhounds have cTnI concentrations higher than non-Greyhound dogs, and that a separate reference range should be established for Greyhounds.
ANIMALS: Blood samples were collected from the jugular vein from a group of 20 healthy Greyhound blood donors.
METHODS: Analysis of serum cTnI was performed with an immunoassay system with a detection level of 0.01 ng/mL, as described previously. The Greyhound values were compared with 2 groups of Boxers with and without arrhythmogenic right ventricular cardiomyopathy (ARVC), and to a group of non-Boxer control dogs from a previous study.
RESULTS: The mean cTnI concentration in Greyhounds was significantly higher (P < .0001) than that in non-Greyhound control dogs, although not significantly different from normal Boxers (P= .50), or Boxers with ARVC (P= .58). Greyhound serum cTnI concentrations were in the range found in Boxers with ARVC. The proposed reference range for cTnI in Greyhounds is 0.05-0.16 ng/mL.
CONCLUSIONS AND CLINICAL IMPORTANCE: Greyhounds have a reference range for serum cTnI concentrations that differs from that of other previously published reference ranges for dogs of other breeds. Until a broader database and more precise reference range can be established, caution should be exercised in interpreting serum cTnI concentrations in Greyhounds with suspected cardiac disease.